Flumazenil, , >99% (HPLC), solid

Not available outside of the UK & Ireland.

Biochem/physiol Actions

Highly specific benzodiazepine receptor antagonist.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

General description

Flumazenil reverses sedative and hypnotic effects of benzodiazepines. It is used to increase acquisition, enhance retention and treat amnesia in mice.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. F6300.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Packaging

25 mg in glass insert

100 mg in poly bottle